Press Releases

Press Releases

View all news
Voronoi Receives Hong Kong IND Approval for VRN11... Expands Global First-Line Treatment Clinical Trial
2026.08.03
■ Following Australia, clinical trial in treatment-naïve patients begins in Hong Kong
■ Expanding first-line treatment clinical trials together with global lung cancer experts... Accelerating development of next-generation EGFR therapy

Voronoi (310210) announced through a disclosure on the 31st that its Phase 1b/2 IND (clinical trial plan) for VRN11, its next-generation EGFR targeted therapy, has been approved by the Department of Health, Hong Kong.

The Hong Kong trial will be led by Professor Molly Li of Prince of Wales Hospital, a world-renowned authority on EGFR non-small cell lung cancer.

VRN11 is currently demonstrating its potential as a next-generation EGFR targeted therapy, having confirmed outstanding efficacy and tolerability in a clinical trial in patients whose disease had progressed despite prior treatment.

In particular, cases in which brain metastases develop after third-generation therapies such as Tagrisso are cited as the area of greatest unmet medical need, as there are no treatment options available.
In this patient group, VRN11 has demonstrated a potent intracranial antitumor effect, with multiple cases of intracranial complete response (CR) confirmed. In addition, the median intracranial progression-free survival (intracranial PFS) has not been reached (Not reached, NR) as of the current analysis, and with 80% of patients continuing treatment, a long-term intracranial disease-suppressing effect of 9 months or more is expected.

Based on these data, with the initiation of a clinical trial in treatment-naïve patients in Hong Kong following Australia, VRN11 will now be put to the test in earnest as a next-generation therapy with the potential to surpass the existing standard of care in the first-line treatment of EGFR mutation lung cancer.

A Voronoi representative said, "We are smoothly expanding the Phase 1b/2 clinical trial in major countries around the world. In addition to the countries where the IND has been approved so far, we are proceeding with country-specific IND (clinical trial plan) approval procedures in Korea, Canada, Singapore, Malaysia, Spain, France, and others."